Interfering RNA against PKC-␣ inhibits TNF-␣-induced IP3R1 expression and improves glomerular filtration rate in rats with fulminant hepatic failure.
INTRODUCTION
Advanced hepatic failure is often accompanied with acute kidney injury (AKI) and has a poor prognosis due to the deterioration of both renal and liver function. Complex mechanisms are likely involved in renal malfunction during severe liver failure, such as alteration in systemic hemodynamics, subsequent renal hypoperfusion, activation of vasoconstrictor systems, and reduced activity of vasodilator systems (13) . Ultimately, renal vasoconstriction leads to a pronounced reduction in the glomerular filtration rate (GFR) (3, 8) . Glomerular mesangial cells (GMCs) regulate glomerular filtration pressure (GFP) by changing glomerular capillary filtration surface area through their contraction (22) . Vascular smooth muscle cells (VSMCs) in preglomerular resistance vessels (interlobular artery and afferent arteriole) mediate constriction or dilation of the vessels (i.e., changes in luminal diameter), in turn regulating renal vascular resistance, renal blood flow, and GFR (2) . Multifactorial mechanisms are involved in abnormal regulation of renal blood flow and GFR (24) . Plasma levels of angiotensin II, endothelin-1 (ET-1), norepinephrine (NE), and tumor necrosis factor-␣ (TNF-␣) are significantly increased in patients with severe liver injury (6, 23) . Cytosolic Ca 2ϩ concentration ([Ca 2ϩ ] i ) in GMCs and VSMCs responds to a couple of external signals and activates various effectors, including cellular contraction (21, 32) . Growing evidence suggests that serum TNF-␣ levels are significantly increased in patients with severe liver injury; meanwhile, TNF-␣ inhibitors, such as pentoxifylline, reduce the incidence of renal failure and mortality of hepatic renal syndrome. Therefore, it is conceivable that TNF-␣ plays a crucial role in the development of renal failure during hepatic insufficiency (1) .
Our previous study demonstrated that rats with fulminant hepatic failure (FHF) exhibited an increased level of serum creatinine (Cr) and enhanced expression of type 1 inositol 1,4,5-trisphosphate receptor (IP 3 R1) protein. At the same time, these rats exhibited a similar trend of increased plasma TNF-␣ and ET-1 levels. Pretreatment with anti-TNF-␣ antibody significantly improved renal function and GFR (29) . TNF-␣ treatment led to an increase in IP 3 R1 expression; in turn, enhanced IP 3 R1 expression amplified the sensitivity of GMCs and VSMCs in response to a variety of vasoconstrictors, thus leading to contraction of these two cell types and resulting in reduced GFR. Our previous findings indicated that TNF-␣ induced IP 3 R1 expression in human mesangial cells through TNFR1/PC-PLC/PKC-␣ and TNFR2 signaling pathways (30) . To further elucidate the role of PKC-␣ in the mediation of IP 3 R1 expression and downstream effects, the present study was aimed at investigating the effects of blocking PKC-␣ by an RNAi approach on renal function and GFR in rats with FHF and acute renal failure. Furthermore, we investigated the TNF-␣/PKC-␣/IP 3 R1 pathway in GMCs to identify target molecules that modulate the pathogenesis of FHF with AKI. Our findings point to a new direction of molecular intervention by directly targeting this novel pathway in severe liver failure with multiple-organ malfunction.
MATERIALS AND METHODS
Sources of materials. TNF-␣, D-galactosamine hydrochloride (GalN), lipopolysaccharide (LPS), fluorescein isothiocyanate (FITCinulin), and ET-1 were obtained from Sigma Chemical (St. Louis, MO). Micro-osmotic pumps at a release rate of 1.0 ml/h were purchased from Durect (Cupertino, CA). Other reagents were obtained as follows: polyclonal IP3R1 antibody was from Synaptic Systems; SP-1 antibody, protein A agarose, and salmon sperm DNA were from Millipore (Billerica, MA); polyclonal PKC-␣ antibody was from BioWorld Technology (St. Louis Park, MN); JNK 1/2/3 polyclonal antibody was from ImmunoWay (Suzhou, Jiangsu, China); p-JNK antibody was from Cell Signaling Technology (Danvers, MA); ␤-actin and GAPDH antibody were from Proteintech Group (Rosemont, PA); goat horseradish peroxidase-conjugated anti-rat/mouse IgG was from Zhongshan Biotechnology (Beijing, China); Lipofectamine RNAiMAX reagent was from Invitrogen (Carlsbad, CA); SP600125 was from Beyotime Technology (Shanghai, China); lentivirus vectors were commissioned by GenePharma (Shanghai, China); and the rat NAG ELISA kit and rat microalbuminuria (MAU/ALB) kit were from Cusabio Life Science (Baltimore, MD).
Small interfering RNA target sequences. Small interfering RNAs (siRNAs) against PKC-␣ and control siRNA were designed by Invitrogen using siRNA software (Waltham, MA). The full-length PKC-␣ gene sequence was retrieved from GenBank (NM_001105713). Three pairs of siRNAs against the rat PKC-␣ gene were designed, and one was selected based on preliminary results. The siRNA sequences were as follows: 5=-GGUUCACAAGAGGUGCCAUTT-3= (sense) and 5=-AUGGCACCUCUUGUGAACCTT-3= (antisense). Universal negative control siRNA sequences were as follows: 5=-UUCUCCGAACG-UGUCACGUTT-3= (sense) and 5=-ACGUGACACGUUCGGAG-AATT-3= (antisense).
Short hairpin RNA (shRNA) against PKC-␣ was converted and synthesized by Genepharma designer based on our siRNA sequence used in the preliminary experiments. The sense sequences of effective PKC-␣ shRNA and negative control oligonucleotide (NC) were as follows: LV-PKC-␣-shRNA: 5=-GGTTCACAAGAGGTGCCAT-3= and LV-NC-shRNA: 5=-TTCTCCGAACGTGTCACGTTTC-3=.
Since siRNA is not stable in vivo and could not transfect nondividing cells and whole model organisms easily, we used an HIV-based lentivector expression construct instead of siRNA. Lentiviral expression vector (LV3-H1-GFP-Puro) was constructed by Genepharma. The packaging plasmids consist of optimized three plasmids: PG-P1-VSVG, PG-P2-REV, and PG-P3-RRE. 293T cells were cotransfected with lentiviral expression construct and packaging plasmids with Lipofectamine 2000. Transfected cells were changed with fresh complete DMEM medium 6 h after transfection and were cultured for another 72 h. Viral particles were collected, and viral transduction unit was determined by counting the number of cells positive for enhanced green fluorescent protein by fluorescent microscopy.
Animal model of FHF and in vivo transduction of lentiviral vector
harboring shRNA against PKC-␣. Our animal experimental procedures were approved by the animal ethic committee of the Chinese Medical University and followed the National Institutes of Health Guide for the Care and Use of Laboratory Animals. Male SpragueDawley rats weighing~220 Ϯ 20 g were housed in stainless steel mesh cages under controlled temperature (23 Ϯ 3°C) and light illumination for 12 h daily. Animals were allowed free access to food and tap water throughout acclimatization for 1 wk and during an entire experimental period. Rats were injected through the tail vein with 1.0 ϫ 10 8 transduction units of lentivirus harboring shRNA against the rat PKC-␣ gene. The timeline of animal experimental design is shown in Fig. 1A .
Preparation of FITC-inulin solution. FITC-inulin (24%) was dissolved in a 0.9% NaCl solution as described previously (18) . To remove residual FITC unbound to inulin, the solution was dialyzed in 1,000 ml of 0.9% NaCl at room temperature for 24 h using a 1,000-Da cutoff dialysis membrane (Spectrum Laboratories, Rancho Dominguez, CA) in the dark and then sterilized by filtration through a 0.22-m filter (18) .
Implantation of micro-osmotic pumps. A total of 36 rats which received injection of lentiviruses harboring shRNA against PKC-␣ or control shRNA 1 wk before were implanted for micro-osmotic pumps. These rats were anesthetized with intraperitoneal injection of pentobarbital sodium (40 mg/kg). Two micro-osmotic pumps filled with 200 l of 8% FITC-inulin were inserted into the peritoneal cavity 7 days before GalN/LPS administration. A pilot study revealed that plasma FITC levels were inadequate for measuring GFR when a single micro-osmotic pump was implanted. After two pumps were implanted, a two-to sixfold increase in plasma fluorescence levels was detected (18) .
Induction of FHF and treatments in different groups. FHF was induced in rats using a combination of GalN (400 mg/kg) plus LPS (32 g/kg) in saline, administrated through tail vein at a volume of 2 ml/kg 2 wk after lentiviral injection and 7 days after intraperitoneal implantation of micro-osmotic pumps (29) . Rats with the implantation of 2 micro-osmotic pumps were randomly divided into four groups 1) N.S. (normal saline) control (n ϭ 6); 2) G/L (GalN/LPS) (n ϭ 10); 3) G/L ϩ LV-shRNA-NC (n ϭ 10); and 4) G/L ϩ LV-shRNA-PKC-␣ (n ϭ 10). After administration of saline and GalN/LPS, all rats were housed individually in metabolic cages. Blood was sampled through the saphenous vein 12 h after exposure to GalN/LPS for GFR measurement. Liver and renal specimens were fixed with 4% paraformaldehyde solution for histopathologic examination. Frozen specimens were used for quantitative analysis of PKC-␣ and IP3R1 by Western blot and real-time RT-PCR analyses. Portions of renal tissues were collected for isolation of glomeruli for the determination of intracellular calcium content and glomerular inulin space (GIS).
Measurement of FITC-inulin in plasma. Because pH significantly affects FITC fluorescent intensity, all plasma samples were buffered to pH 7.4 with 500 mM HEPES (18) . Fluorescent intensity was determined using Thermo Scientific Varioskan Flash with excitation at 485 nm and emission at 538 nm.
A standard curve for blood samples was generated using FITCinulin concentrations of 0 -2.5 g/ml. The linear correlation between fluorescent intensity and inulin concentration was established by measuring fluorescent intensity in serial dilutions of an FITC-inulin solution of known concentration. A regression coefficient of 0.99 was achieved between fluorescent readings and plasma FITC-inulin concentration, confirming the reliability of Thermo Scientific Varioskan Flash to measure FITC-inulin.
Calculation of GFR. GFR was evaluated 12 h after GalN/LPS exposure and 7 days after implantation of micro-osmotic pumps based on the inulin clearance equation (inulin clearance ϭ inulin infusion rate/steady-state blood inulin concentration), as we described previously (29) . GFR1 was expressed in microliters per minute (ml/min), and GFR2 was corrected further by kilogram body weight (ml·min Ϫ1 ·kg body wt Ϫ1 ). GFR3 was calculated in microliters per minute per gram kidney weight (ml·min Ϫ1 ·g kidney wt Ϫ1 ). GFR2 and GFR3 reflect the GFR more precisely than GFR1 due to a further correction by body and kidney weight (29) .
Isolation of glomeruli from rats exposed to GalN/LPS. Glomeruli were isolated by a gradual sieving technique. Briefly, the renal capsule was removed and the cortex was minced with a razor blade to a paste-like consistency and strained through a 250-m steel sieve. The suspension was further filtered through two consecutive steel sieves (120 and 70 m). The glomeruli that were retained at the top of a 70-m sieve were washed and resuspended in ice-cold PBS. Tubular contamination was Ͻ5%, as assessed under a light microscope. The entire procedure was performed in an ice bath within 1 h (26, 28) . Isolated glomeruli were used for [Ca 2ϩ ]i and GIS measurements. [Ca 2ϩ ]i measurement in glomeruli. A total of 4,000 glomeruli were suspended in 400 l of Hank's saline solution (containing 1% bovine serum albumin). Glomeruli were incubated with fura-2-AM (10 M; Dojindo, Tokyo, Japan) at 37°C in a shaking water bath in dark for 45 min. Fluorescent excitation of fura-2 was performed at 340/380 nm, and emission was detected above 510 nm. After the base line was recorded, the ratio of fluorescent intensity (340/380 nm) for each sample was recorded under treatment with ET-1 (100 nM; Sigma). Cytosolic [Ca 2ϩ ]i in glomeruli was measured during a 0.1 s exposure at 20.0-s intervals for 10 min using Thermo Scientific Varioskan Flash. At the end of each experiment, CaCl2 (2.5 ϫ 10 Ϫ3 M) and EGTA (5 mM) were added to obtain maximal fluorescent intensity (F max) and minimal fluorescence (Fmin), respectively. The calculation equation of calcium concentration was as follows (7, 27) 
Determination of GIS. Approximately 4,000 glomeruli were suspended in 400 l of ice-cold Ca 2ϩ -free buffer solution containing 1% bovine serum albumin, incubated with FITC-inulin (100 g) at 37°C in a shaking water bath for 30 min and then equally divided into two parts. Half of the glomeruli were treated with ET-1 (100 nM) for 10 min, and the rest of the glomeruli were used as a control. After ET-1 treatment, glomeruli were centrifuged at 5,000 g for 5 s. Twenty microliters of supernatant and whole glomerular pellets were separately suspended in 500 l of 0.3% Triton X-100 solution overnight. Fluorescent intensity (FI) of glomeruli was measured with Thermo Scientific Varioskan Flash. GIS of a single glomerulus was calculated as follows (26, 28) :
Serum biochemical analysis. Serum levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST), creatinine (Cr), blood urea nitrogen (BUN), potassium (K ϩ ), sodium ion (Na ϩ ), chloride ion (Cl Ϫ ), TNF-␣, and ET-1 were determined using commercial kits. Serum levels of TNF-␣ and ET-1 were quantified by ELISA using commercial kits (R&D Systems, Abingdon, UK).
Proteinuria, albuminuria, and urine N-acetyl-␤-D-glucosaminidase analysis. The urine samples were collected over 12 h from rats placed in metabolic cages. Protein concentration was measured using a modified Lowry assay. Urine levels of albuminuria and N-acetyl-␤-D-glucosaminidase (NAG) were performed by ELISA as instructed by the manufacturers and used to be indicators of renal tubular injury.
Histologic analysis. Liver and kidney specimens were fixed in 10% formalin and embedded in paraffin for histopathological analysis.
Electronic microscopy specimen preparation and examination. The electronic microscopy preparation of renal cortex specimens was performed as described previously (15), and the sections were observed in JEOL JEM 1230 Transmission Electron Microscope (29) .
Cell culture and transfection. A GMC line (CRL-2573) was obtained from American Type Culture Collection (Manassas, VA). GMC cells were cultured at 37°C in a 5% CO 2 humidified incubator with high-glucose DMEM medium containing 10% FBS, 100 U/l penicillin, and 100 mg/l streptomycin (12) .
Cells were plated in six-well plates (35 mm) and grown to 60 -80% confluence at the time of transfection. Before transfection, RNAi duplex-Lipofectamine RNAiMAX complexes were prepared following the manufacturer's protocol based on preliminary results. Cells were cultured with Lipofectamine RNAiMAX reagent plus siRNA at a ratio of 6 l:6 l (120 pmol), respectively. After 6 h, 2 ml of fresh complete DMEM medium were changed and cells were cultured for 24 h. Cells were divided into four groups 1) siRNA-NC; 2) siRNA-NC ϩ TNF-␣; 3) siRNA-PKC-␣; and 4) siRNA-PKC-␣ ϩ TNF-␣. TNF-␣ (100 ng/ml) was added 24 h before cells were collected.
Treatments of GMCs with TNF-␣. GMCs were stimulated with TNF-␣ (100 ng/ml) for 2 to 24 h before being harvested for RNA or protein extraction (30) .
[Ca 2ϩ ]i measurement in transfected GMCs. GMCs transfected with siRNA against PKC-␣ were treated with TNF-␣ (100 ng/ml) for 24 h, then digested with 0.25% trypsin, and suspended in complete DMEM medium. Cytosolic [Ca 2ϩ ]i in GMCs was measured during a 0.1-s exposure at 6.0-s intervals for 3 min using Thermo Scientific Varioskan Flash. Other process and formula were the same as [Ca 2ϩ ]i measurement in glomeruli (7, 27) .
Real-time quantitative RT-PCR. Total RNA was isolated from the scaffold using a Trizol (Takara)-based protocol. The concentration and purity of mRNA were determined by spectrophotometry at 260 and 280 nm and diluted to 500 ng/l with DEPC-treated water. RNA was incubated at 37°C for 15 min, followed by 85°C for 5 s for reverse transcription to generate cDNA. The cDNA underwent 40 cycles of PCR (95°C for 30 s, 95°C for 5 s, and 60°C for 30 s) in TP800 Thermal Cycler Dice Real Time System (Takara). Primer sequences of rat IP 3R1 were 5=-TCTGGCCAGCTGTCAGAACTAAAG-3= (forward) and 5=-GTGGGTTGACATTCATGTGAGGA-3= (reverse). Primer sequences of rat PKC-␣ were 5=-TCCAGGATGACGACG-TGGAG-3= (forward) and 5=-CGTTGACGTATTCCATGACGA-AG-3= (reverse). Primer sequences of rat GAPDH were 5=-GAC-AACTTTGGCATCGTGGA-3= (forward) and 5=-GACAACTTTG-GCATCGTGGA-3= (reverse). Relative levels of IP 3R1 and PKC-␣ gene expression were calculated based on amplification of a standard curve after a series of cDNA dilutions. GAPDH was used as a housekeeping control. Each sample was assayed in triplicate (29) .
Western blot analysis of IP 3R1. To detect PKC-␣, SP-1, JNK/p-JNK, and IP 3R1 proteins, cells were treated and washed with ice-cold 
Morphology of GalN/LPS-induced acute liver injury in all groups. Liver histology from rats 12 h after treatment with GalN/LPS shows massive hemorrhage and necrosis. Extensive necrosis is accompanied with fracture of hepatocellular cords, loss of lobular structure, sinusoid expansion, and Kupffer cell proliferation. Damaged hepatocytes appear to have their nuclei dissolved with nuclear debris or pycnosis. Severe liver necrosis is accompanied by biliary ductular reaction (B, C1) and sinusoidal congestion (B, B1, C1, and D1) as seen 12 h after GalN/LPS challenge. No changes in liver morphology were observed between G/L ϩ LV-shRNA-NC group and G/L ϩ LV-shRNA-PKC-␣ group. None of the GalN/LPS-exposed rats had obvious morphologic alterations in the glomerulus or proximal and distal tubule of rats with GalN/LPS exposure. Hematoxylin and eosin staining is shown with magnification at ϫ400.
PBS. Total cell protein was extracted in RIPA lysis buffer (Beyotime, Shanghai, China) and total renal tissue protein was extracted using T-PER Tissue Protein Extraction (Thermo, Rockford, UIL), followed by centrifugation (12,000 g, 12 min). Protein concentration was determined with a BCA protein assay reagent kit (Pierce Biotechnology, Thermo). Equal amounts of protein were applied to 7% (for IP3R1) or 10% (for SP-1 and PKC-␣) SDS-PAGE and electrophoresed. Proteins were transferred onto a PVDF membrane (Millipore), which was blocked with 5% fat-free milk for 2 h. After blocking, the PVDF membrane was immunoblotted with a primary antibody (polyclonal IP3R1 antibody, polyclonal PKC-␣ antibody, SP-1 antibody, or JNK/p-JNK antibody) overnight. The membrane was washed three times with a Tris·HCl-NaCl-Tween 20 solution to remove unbound antibody. The membrane was then incubated with horseradish peroxidase-conjugated goat-anti-rabbit IgG for 1 h at room temperature. The membrane was washed three times with Tris·HCl-NaCl-Tween 20 to remove unbound secondary antibody and developed with a Luminol chemiluminescent detection kit (Pierce Biotechnology, Thermo). Protein expression was quantified by densitometry. ␤-Actin and GAPDH were used internal loading controls. Relative protein levels were calculated based on a densitometric count ratio of IP3R1 over ␤-actin bands (29) .
Chromatin immunoprecipitation. Chromatin immunoprecipitation (ChIP) assays were performed as described by Svoteliset et al. (25) . Cells were transfected with siRNA against PKC-␣ or control siRNA using Lipofectamine RNAiMAX, and the culture medium was replaced with fresh complete DMEM 6 h after transfection. Cells were cross linked in medium containing 1% formaldehyde for 10 min at 37°C before the reaction was stopped with glycine 24 h after transfection. Cells were resuspended in SDS lysis buffer (1% SDS, 10 mM EDTA, and 50 mM Tris·HCl, pH 8.1) with 1ϫ protease inhibitor cocktail (Roche Molecular Biochemicals, Indianapolis, IN) and sonicated with a Handy Sonic (model UR-20P) for six cycles of 10 s at 60% attitude followed by centrifugation at 14,000 g in 4°C for 10 min to obtain DNA fragments between 200 and 500 bp. Supernatants were collected and diluted in ChIP dilution buffer (0.01% SDS, 1.1% Triton, 1.2 mM EDTA, and 167 mM Tris·HCl, pH 8.1) followed by immunoclearing with protein A agarose/salmon sperm DNA (Millipore) for 30 min at 4°C. ChIP preparations were incubated overnight at 4°C with specific antibodies. Protein A agarose/salmon sperm DNA was added and washed sequentially with low-salt buffer, high-salt buffer, LiCl buffer, and 1ϫ TE buffer. Protein-DNA complexes were eluted, and crosslinking was reversed at 65°C overnight. DNA fragments were purified by phenol/chloroform and absolute ethyl alcohol and analyzed by PCR. Primer sequences for the IP 3R1 promoter region were 5=-TTCCGGGCCTATATAAGCGG-3= (forward) and 5=-GTTAGGATGGGAGCGGAACA-3= (reverse). Immunoprecipitated DNA was amplified by PCR for 45 cycles (95°C for 15 s, 57°C for 15 s, and 72°C for 20 s) with the touchdown amplification protocol used for chemokine expression analysis.
Statistical analysis. All results presented are representative of at least three separate experiments and are expressed as means Ϯ SE. SPSS version 17.0 software was used for statistical analysis and compared using one-factor ANOVA and least significant difference for multiple comparisons between groups. P Ͻ 0.05 was considered statistically significant.
RESULTS

Renal failure model induced by GalN/LPS treatment.
Liver tissues stained with hematoxylin and eosin presented histologically extensive hepatic necrosis and severe hemorrhage in part of lobules. Extensive necrosis is accompanied with fracture of hepatocellular cord, loss of lobular structure, sinusoid expansion, and Kupffer cell proliferation. Damaged hepatocytes appear to have their nuclei dissolved with nuclear debris or pycnosis. Severe liver necrosis is accompanied by biliary ductular reaction (Fig. 1B, C1 ) and sinusoidal congestion (Fig.  1B, B1, C1 , and D1) as seen 12 h after GalN/LPS challenge. None of the GalN/LPS-exposed rats had obvious renal morphologic alterations in histological examination (Fig. 1B) . Micrographs of electronic microscopy did not show any abnormalities in renal cortex in all groups (Fig. 2) . Representing marked renal dysfunction without structural or histologic alteration in severe hepatic damage is the characteristics of acute renal insufficiency and is a valuable model for testing molecular intervention with an RNAi approach.
Effect of silencing PKC-␣ in animals with FHF. G/L group mortality reached 40% (4/10) 12 h after the administration of GalN/LPS, 39% (9/13) in G/L ϩ LV-shRNA-NC group, and 32% (8/25) in G/L ϩ LV-shRNA-PKC-␣ group. GalN/LPS treatment led to a marked increase in serum ALT (up to 65-fold), AST (up to 216-fold), Cr (1.6-fold), BUN (up to 3.2-fold), TNF-␣ (up to 7.2-fold), and ET-1 (up to 5.6-fold) levels ( Table 1) . Preadministration of lentivirus harboring shRNA against PKC-␣ attenuated renal failure in FHF rats as indicated by improved BUN (down by 50%) and Cr (down by 33.7%) in the G/LϩLV-shRNA-PKC-␣ group in comparison with the G/L and G/L ϩ LV-shRNA-NC groups (Table 1) and partially improved rat mortality from nearly 40 to 32%.
Suppressing PKC-␣ expression increased GFR in rats with FHF. FITC-inulin clearance was measured under a steady-state condition to reflect GFR. After implantation of microosmotic pumps in the peritoneal cavity, rats experienced a significant weight loss over a few days and then gradually recovered to preoperative body weight by day 7. Thus inulin clearance was determined 7 days after implantation of microosmotic pumps and 12 h after GalN/LPS exposure. GFR was calculated from plasma inulin levels and a known pump infusion rate. GalN/ LPS intoxication decreased GFR 1 in the G/L and G/L ϩ LV-shRNA-NC groups by 31 and 37% of the N.S. controls, respectively. GFR 1 values in the G/L ϩ LV-shRNA-PKC-␣ group were significantly restored compared with the G/L and G/L ϩ LV-shRNA-NC groups (80 and 50%). GFR values are presented in Table 1 after correction with body weight (per kilogram, GFR 2 ) and kidney weight (per gram, GFR 3 ). These data confirmed renal malfunction during FHF caused by GalN/ LPS intoxication and prevention of renal insufficiency by PKC-␣ shRNA lentiviral administration.
Proteinuria, albuminuria, and urine NAG in FHF rats. GalN/LPS treatment did NOT cause a marked increase in proteinuria, albuminuria, and urine NAG levels in FHF rats. There is no significant difference in NAG (one of the urinary tubular injury biomarkers) levels between controls and GalN/ LPS-exposed rats and those receiving PKC-␣ shRNA lentiviral administration ( Table 2) .
Effects of PKC-␣ inhibition on PKC-␣ and IP 3 R1 expression in renal tissue.
Quantitative RT-PCR was performed to determine PKC-␣ and IP 3 R1 mRNA expression in renal tissue. 
ALT, IU/l 51. Table 2 . Levels of proteinuria, albuminuria, and urine NAG 3.20, P Ͻ 0.01) mRNA levels in the G/L ϩ LV-shRNA-PKC-␣ group were markedly decreased (Fig. 3, A and B ] i levels compared with the G/L ϩ LV-shRNA-NC group (2.22 vs. 1.24, P Ͻ 0.01) (Fig. 3E) . Changes in GIS reflect glomerular size and indirectly indicate vascular dilation/constriction sta- tus. Ratios of GIS 2 (treated with ET-1) over GIS 1 (control) are shown in Fig. 3F . The GIS ratios in the G/L (1 vs. 0.51, P Ͻ 0.01) and G/L ϩ LV-shRNA-NC (1 vs. 0.56, P Ͻ 0.01) groups were markedly decreased compared with the N.S. controls. The ratios were not statistically different between the G/L ϩ LV-shRNA-NC group and the G/L group. The GIS ratio in the G/L ϩ LV-shRNA-PKC-␣ group was restored compared with the G/L ϩ LV-shRNA-NC group (0.56 vs. 0.70, P Ͻ 0.01), indicating that PKC-␣ plays a critical role in modulating renal vascular constriction. We observed that AKI and decrease of GFR in FHF rats caused by GalN/LPS exposure were accompanied with upregulated IP 3 R1 expression and increasing glomerular calcium content. The PKC-␣ silencing in FHF rats improved these abnormalities. However, the molecular mechanisms of how PKC-␣ silencing attenuated the extent of AKI in FHF are not fully understand. Therefore, we employed GMCs to further investigate the effects on TNF-␣ on PKC-␣ and IP 3 R1.
TNF-␣-stimulated PKC-␣ and IP 3 R1 expression in GMCs.
We further investigated the molecular mechanism of TNF-␣ on PKC-␣ and IP 3 R1 expression in GMCs. Quantitative analysis demonstrated that PKC-␣ mRNA started to increase at 4 h and reached higher levels at 8 h after TNF-␣ treatment (P Ͻ 0.05), which were sustained till 24 h (Fig. 4A) . The expression levels of PKC-␣ protein expression started to increase at 4 h, reached the highest at 8 h (P Ͻ 0.05), and returned to nearly a basal level by 24 h (Fig. 4B) . A significant induction of IP 3 R1 mRNA occurred by 2 h after TNF-␣ treatment, reached a maximum at 8 h (P Ͻ 0.01) compared with basal levels, and returned to a basal level at 24 h (Fig. 4C ). Compared with the basal level, IP 3 R1 protein levels started to increase at 4 h after TNF-␣ treatment, increased to the highest levels at 8 h, and were sustained for 24 h (P Ͻ 0.05) (Fig. 4D) . We observed an increase in mRNA levels before an increase in protein levels. The increase in IP 3 R1 mRNA levels by TNF-␣ stimulation could be partly due to an effect on transcription of IP 3 R1 gene. The increased expression of IP 3 R1 may be partly due to increased synthesis of the PKC-␣.
The effect of silencing PKC-␣ on TNF-␣-stimulated IP 3 R1 expression and the change of cytosolic [Ca 2ϩ ] i after ET stimulation in GMCs. PKC-␣ mRNA expression in GMC cells transfected with siRNA was determined by real-time RT-PCR 8 h after TNF-␣ treatment. Western blot analysis was performed to determine IP 3 R1 and PKC-␣ protein levels 24 h after TNF-␣ treatment. Compared with the siRNA-NC group, PKC-␣ mRNA (2.69-fold) and protein (2.45-fold) expression was significantly increased (P Ͻ 0.01) by TNF-␣ treatment (Fig. 5, A and C) . There was a marked decrease in PKC-␣ mRNA and protein expression levels after PKC-␣ silencing (P Ͻ 0.01). TNF-␣ treatment resulted in enhanced IP 3 R1 expression at both the mRNA (2.53-fold) and protein (2.85-fold) levels in the siRNA-NC ϩ TNF-␣ group compared with the siRNA-NC group (P Ͻ 0.01) (Fig. 5, B and D) . Compared with TNF-␣ stimulation alone, silencing PKC-␣ suppressed TNF-␣-induced expression of IP 3 R1 at the mRNA and protein levels (P Ͻ 0.01) (Fig. 5, B and D) . ET-1 is a potent vasoconstrictor of the renal vascular bed. The ratio of cytosolic [Ca 2ϩ ] i in GMCs treated with ET-1 over basal [Ca 2ϩ ] i is shown in Fig.   5E . Using the Ca 2ϩ -sensitive dye fura-2-AM, we were able to show that ET-1 triggered a marked increase in the [Ca 2ϩ ] i ratio in GMC cells in the first, second and third minute in the siRNA-NC ϩ TNF-␣ group (P Ͻ 0.05). Silencing PKC-␣ completely abrogated ET-1-elicited release of restored [Ca 2ϩ ] i in both siRNA-PKC-␣ and siRNA-PKC-␣ ϩ TNF-␣ groups (P Ͻ 0.01).
TNF-␣ regulates SP-1 expression and its binding to the IP 3 R1 promoter. SP-1 protein expression was obviously increased 2-24 h after TNF-␣ treatment and reached peak levels at 8 h (P Ͻ 0.01) (Fig. 6A) . GMCs were treated with TNF-␣ for 4 -24 h, and the ChIP assay was performed with SP-1 antibody and primers specific to the SP-1 binding site in the IP 3 R1 promoter region. The findings demonstrated that TNF-␣ treat- quantitative results of PKC-␣/GAPDH mRNA ratios using the controls as a reference (n ϭ 3). B: quantitative results of IP3R1/GAPDH mRNA ratios using the controls as a reference (n ϭ 3). C: representative Western blots for PKC-␣ protein and quantitative results of PKC-␣/␤-actin densitometry (n ϭ 3). D: representative Western blots for IP3R1 protein and quantitative results of IP3R1/␤-actin densitometry (n ϭ 6). E: ratio of sustained [Ca 2ϩ ]i over basal levels was used to show changes in calcium levels after TNF-␣ exposure and PKC-␣ silencing. Data represent the means Ϯ SE (n ϭ 3). **P Ͻ 0.01, compared with siRNA-NC group. ##P Ͻ 0.01, compared with siRNA-NC ϩ TNF-␣ group. ment remarkably enhanced SP-1 binding to the IP 3 R1 promoter in GMCs with a maximal effect seen at 8 h (Fig. 6B ). TNF-␣ (100 ng/ml) was added 8 h before cells were collected. Compared with the siRNA-NC group, SP-1 protein expression was significantly increased (P Ͻ 0.01) by TNF-␣ treatment, and this trend was significantly mitigated by transfection with siRNA against PKC-␣ (Fig. 6C ) (P Ͻ 0.05). PKC-␣ silencing also suppressed the increased binding activity of SP-1 to the IP 3 R1 promoter caused by TNF-␣ exposure (Fig. 6D) . Therefore, the findings confirmed that SP-1 is the transcription factor governing the IP 3 R1 expression in GMCs exposed to TNF-␣.
Effects of PKC-␣ silence on JNK/p-JNK expression. Significant induction of JNK and p-JNK protein occurred by 2 h after TNF-␣ treatment and reached a maximum level at 8 h (P Ͻ 0.01 and P Ͻ 0.05, respectively) compared with the basal levels. JNK and p-JNK protein levels were returned at 24 h (Fig. 7, A and B) . Compared with the siRNA-NC group, JNK and p-JNK protein expression in siRNA-NC ϩ TNF-␣ group was significantly increased (P Ͻ 0.05). It is evident from Fig.  7 , C and D, that silencing PKC-␣ suppressed TNF-␣-induced expression of JNK and the p-JNK protein in GMCs (P Ͻ 0.05).
Involvement JNK activation in TNF-␣-induced IP 3 R1
expression. GMCs were treated with a JNK inhibitor, SP600125 (10 mol/l), for 1 h before exposure to TNF-␣. The addition of SP600125 was sufficient to cause almost completely abrogated TNF-␣-stimulated increase in SP-1 protein level (P Ͻ 0.01) (Fig. 8A) . SP600125 suppressed TNF-␣-stimulated IP 3 R1 expression at both mRNA and protein levels (P Ͻ 0.01) (Fig. 8, B and C) . These results point to a positive regulatory role of PKC-␣ and JNK signaling in TNF-␣-induced expression of IP 3 R1 in GMCs.
DISCUSSION
Fulminant or subacute hepatic failure or end-stage liver disease often accompanies AKI, and the multiple organ failure evidently increases patient mortality. There are several hypotheses regarding how AKI happens during FHF (31) . A widely recognized hypothesis is when FHF occurs, the internal organs and peripheral vessels become dilated, which reduces the effective blood volume and causes overexcitation of the sympathetic nerve and renin-angiotonin systems. Endogenous vasoconstrictors, such as vasopressins (e.g., angiotonin II and norepinephrine), increase the pressure of peripheral vascular beds (including the preglomerular arteriole) and arteries (renal hypoperfusion), and the consequence is uncontrolled constriction of preglomerular vessels (14) . Therefore, it is conceivable that the strong constriction of renal vessels may be the dominant pathogenesis of renal failure during FHF; however, the signaling pathway underlying renal vessel constriction remains to be elucidated in an appropriate animal model. TNF-␣ is an important cytokine in the development of renal disease and severe hepatopathy, and TNF-␣ levels are positively correlated with the severity of renal diseases (5) . Administration of TNF-␣ antibody attenuated the renal insufficiency in FHF rats (29) . These clinical or laboratory studies suggest that TNF-␣ plays an indispensable role in the development of AKI during FHF and may be a key factor that is directly or indirectly responsible for a reduction of GFR as shown in Table 1 . IP 3 R1 is an important Ca 2ϩ release channel present primarily in renal GMCs and VSMCs (11) . Many factors, such as TNF-␣, trigger IP 3 R1 expression, and in turn cause subsequent Ca 2ϩ imbalance and increased cell contraction sensitivity during the progression of renal failure (4, 33) . In clinical observations, serum levels of TNF-␣, ET-1, and other vasoconstrictors are significantly elevated during the development of FHF, and ET-1 elicits IP 3 production as a potent vasoconstrictor of the renal vascular bed (6, 21, 23 32) . The elevation of IP 3 R expression in GMCs and VSMCs as observed in the present study provides more binding sites for the IP 3 ligand, promotes IP 3 -mediated Ca 2ϩ mobilization, and increases cell susceptibility to vasoconstrictor (e.g., ET-1). Cytosolic Ca 2ϩ reserved in the endoplasmic reticulum is released into the cytoplasm, and this triggers contraction of GMCs and VSMCs, reduces glomerular filtration area, and decreases renal blood flow, thereby further compromises GFR. Thus it is well accepted that increase in cytosolic Ca 2ϩ content could be an intermediate factor triggering the constriction of GMCs and/or VSMCs for the increase in renal circulation resistance and is responsible for reduced GFR (4, 11, 33) .
In the present study, we observed a significant elevation of the Cr level but a marked decrease of GFR in FHF rats caused by GalN/LPS challenge accompanied with significant increase in serum levels of TNF-␣ and ET-1. This renal insufficiency did not seem to be caused by significant glomerular or tubular damage since it is not supported by renal histopathology and urine albuminuria and NAG levels. A significant increase in mRNA and protein levels for IP 3 R1 in renal tissues was accompanied with renal insufficiency in this animal model of renal insufficiency. During the development of FHF in animal model, serum levels of TNF-␣ and ET-1 and renal dysfunction are manifestations similar to FHF patients in clinical observation. In our previous study, we have demonstrated that TNF-␣ play a key role during FHF accompanied with AKI (29) . PKC-␣ activation is under the control of TNF-␣ activity (30) . Therefore, PKC-␣ silencing in FHF rats improved the renal function and GFR levels and decreased IP 3 R1 mRNA and protein expression levels. The increase in glomerular calcium content and GIS levels was accompanied with FHF rats and silencing PKC-␣ corrected these abnormalities. Thus the findings from our animal model of FHF with renal insufficiency largely support the proposed mechanisms of acute renal dysfunction during severe liver failure (14, 31) .
PKC is widely distributed in various tissues and participates in numerous signaling cascades. PKC-␣ is the major isoform existing in kidneys and plays a very important role in maintaining normal renal function (16) . Mesangial cell dilation and constriction are tightly under the control of PKC activation (9) . Notably, TNF-␣ upregulates IP 3 R1 expression via two independent signaling pathways (TNFR1/PC-PLC/PKC-␣ and TNFR2) (30) . In the present study, our findings demonstrated that lentivirus-mediated PKC-␣ silence significantly suppressed the elevation of serum creatinine level in rats secondary to FHF, markedly improved GFR, and reduced the expression of IP 3 R1 mRNA and protein levels in renal tissues. At the same time, Ca 2ϩ levels were reduced in glomeruli from rats receiving injection of lentiviral vector harboring shRNA against PKC-␣. Therefore, it is our speculation that PKC-␣ silencing reduces intracellular Ca 2ϩ release by suppressing IP 3 R1 expression in GMCs and VSMCs during FHF and improves GFR through the inhibition of cell contraction and reduction of GIS. In this process, it is most likely that PKC-␣ is an important molecule through which TNF-␣ upregulates IP 3 R1 expression, and it is not surprising that PKC-␣ silencing exhibits a protective effect on renal insufficiency.
To investigate the cellular pathway of IP 3 R1 upregulation mediated by the TNF-␣ϪPKC-␣ pathway, we further explore the molecular signaling mechanisms. TNF-␣ treatment in GMCs clearly increased the mRNA and protein levels of both PKC-␣ and IP 3 R1, markedly enhanced cellular sensitivity to ET-1, and elevated intracellular calcium release. Thus RNA interference of PKC-␣ expression in GMCs significantly abrogated TNF-␣-mediated upregulation of IP 3 R1 mRNA and protein expression and markedly suppressed ET-1-mediated elevation of Ca 2ϩ concentration in TNF-␣-treated GMCs. We hypothesized that TNF-␣-stimulated upregulation of IP 3 R1 expression may affect IP 3 R1 transcription by increasing the IP 3 R1 mRNA level. To test this hypothesis, we used a ChIP technology based on the following understanding. The transcription factor SP-1 is reported to be necessary for TNF-␣ regulation of IP 3 R1 expression in mouse nerve cells (17) . However, these events have not yet been investigated in renal cells. Our results revealed that TNF-␣ treatment resulted in an increase, reaching a peak at 8 h, in SP-1 protein expression, and the phase of increased expression was coincident with that of IP 3 R1 mRNA expression. ChIP experiments proved that the strongest binding of SP-1 to the IP 3 R1 promoter occurred during this time frame, suggesting that TNF-␣ affected the promoter activity by enhancing SP-1 protein expression and promoter binding, subsequently elevating IP 3 R1 mRNA levels and further influencing IP 3 R1 protein expression. Given the fact that siRNA-PKC-␣ significantly suppressed TNF-␣-stimulated increase of SP-1 protein expression and the binding of SP-1 protein to the IP 3 R1 promoter, it is conceivable that PKC-␣ affected IP 3 R1 expression at a transcriptional level through the SP-1 transcription factor and that the PKC-␣-SP-1 route is critical for TNF-␣ to modulate IP 3 R1 expression during renal insufficiency.
Mitogen-activated protein kinase (MAPK) is a serine/threonine protein kinase that is widely distributed in cells. The MAPK family includes ERK, JNK-SAPK, and p38, which are crucial in regulating cell proliferation, differentiation, and gene transcription in response to extracellular signals (20) . It is reported that PKC-␣ regulates expression of both JNK and p-JNK (10, 19) . We found a marked elevation of JNK and p-JNK expression in the TNF-␣-treated GMCs, and the phase of elevated expression was consistent with the changes of SP-1 levels. PKC-␣ silencing exerted a mild effect on JNK and p-JNK protein levels compared with the siRNA-NC group but did attenuate TNF-␣-stimulated increase in JNK and p-JNK protein levels. Pretreatment with SP600125 (JNK inhibitor) suppressed TNF-␣-stimulated elevation of SP-1 protein expression and significantly inhibited the downstream increase in IP 3 R1 mRNA and protein expression levels. These findings indicate that TNF-␣ may upregulate JNK/p-JNK expression via PKC-␣ and JNK might participate in the TNF-␣-elicited IP 3 R1 expression pathway. The net effect would ultimately change SP-1 protein expression and affect IP 3 R1 expression. Taken together, our findings demonstrate that TNF-␣ upregulates IP 3 R1 expression via the JNK/SP-1 pathway (a downstream pathway of PKC-␣) in GMCs. However, it remains to be investigated whether TNF-␣ affects IP 3 R1 expression via ERK and p38 from the MAPK family, and how potential interactions of TNF-␣ with PKC-␣ and SP-1 take place in the event of acute renal insufficiency during FHF.
In conclusion, the findings in the present study demonstrate that PKC-␣ silencing improves renal function and GFR, and suggest that TNF-␣ is critical in the mediation of renal failure during FHF by binding to the IP 3 R1 promoter via the PKC-␣/ JNK/SP-1 pathway and in turn upregulating IP 3 R1 expression at a transcriptional level. Collectively, this study confers concept-proving evidence of a novel molecular intervention by directly targeting the PKC-␣/JNK/SP-1 pathway in severe liver failure with renal insufficiency.
